

1 Modulation of host signalling pathways reveal a major role for Wnt  
2 signalling in the maturation of *Plasmodium falciparum* liver schizonts

3 Abhishek Kanyal<sup>1\*</sup>, Geert-Jan van Gemert<sup>2\*</sup>, Haoyu Wu<sup>1,3\*</sup>, Alex van der Starre<sup>2</sup>, Johannes  
4 HW de Wilt<sup>4</sup>, Teun Bousema<sup>2</sup>, Robert W. Sauerwein<sup>2</sup>, Richard Bartfai<sup>1\*</sup>, Annie SP Yang<sup>2,5,6\*</sup>

5 \*these authors contributed equally

6 1. Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular  
7 Life Science, Radboud University, Nijmegen, The Netherlands

8 2. Radboud Center of Infectious Diseases, Department of Medical Microbiology, Radboud  
9 University Medical Center, Nijmegen, the Netherlands

10 3. CAS Key Laboratory of Regenerative Biology, Guangzhou Institutes of Biomedicine and  
11 Health, Chinese Academy of Sciences, Guangzhou 510530, China

12 4. Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands

13 5. Present address: Department of Parasitology, Leiden University Center for Infectious  
14 Diseases, Leiden University Medical Center, Leiden, the Netherlands

15 6. Lead contact.

16 Correspondence: a.s.yang@lumc.nl (ASPY) or r.bartfai@science.ru.nl (RB)

17

18 **Abstract:**

19 After infection of the human host, the initial stage of the *Plasmodium falciparum* (Pf) lifecycle  
20 takes place in the liver. However, understanding of the host-parasite interaction has been  
21 limited by the rapid loss of functionality in cultured primary human hepatocytes (PHHs). Here,  
22 we link loss of hepatic functionality to drastic loss in Pf permissiveness, which we effectively  
23 prevent by using a novel medium containing serum-replacement and signal transduction  
24 inhibitors. Integrating transcriptomic analysis and phenotypic assessment of infection outcome,  
25 we identified several host signalling pathways that influence Pf liver stage development.  
26 Inhibition of the Wnt pathway in particular plays a major role in determining the size and  
27 maturity of Pf-liver schizonts, via retaining metabolic activity and epithelial nature of  
28 hepatocytes. Host signalling pathways determining Pf liver stage permissiveness provide  
29 insight into the complex host-parasite interaction and may accelerate development of novel  
30 therapeutic strategies for Pf-liver stages. (145)

31

32

33

34 **Introduction**

35 The mosquito-borne disease, malaria, remains a devastating global burden with approximately  
36 250 million cases and 620,000 deaths annually [1]. Most of the deaths are due to the parasite  
37 *Plasmodium falciparum* (Pf), which begins its developmental life-cycle inside liver cells  
38 (hepatocytes) after initial deposition into the skin by an infected mosquito. Over a period of  
39 approximately one week, a small number of these parasites (sporozoites) will replicate and  
40 differentiate into intracellular schizont, each containing approximately 90000 blood-infective  
41 daughter merozoites [2]. The release of these merozoites into the circulation and their  
42 subsequent cyclical asexual replication in red blood cells (RBCs) is responsible for clinical  
43 symptoms associated with the disease.

44

45 Despite its fundamental importance in enabling effective infection, currently fundamental  
46 understanding of the complex parasite-host interaction within the infected hepatocytes remains  
47 elusive. Studies with the rodent *Plasmodium berghei* (Pb) model have been informative as a  
48 proxy for Pf but findings are often not translatable to Pf-host interactions as in particular the  
49 rodent parasite has only a 2-day liver-stage period compared to 7-days for Pf [3]. Specific host  
50 membrane receptors have been identified to be involved in Pb sporozoite invasion of  
51 hepatocytes such as CD81 and Scavenger Receptor B1 (SR-B1) [4-6]; similarly, host factors  
52 involved in nutrient acquisition [7-10] and/or prevention of host cell death pathways [11-14].

53

54 Research in Pf primarily involves *in vivo* models such as mice with humanised liver [2, 15, 16]  
55 or *in vitro* models where hepatocyte cell-lines such as HC-04 [17, 18] and primary human  
56 hepatocytes (PHHs) are used. The usage of cell-lines has been limited to the identification of  
57 host receptors involved in parasite invasion such as EphA2 [19] and glypican 3 [18].  
58 Contrastingly, PHHs are considered the gold standard in drug assays [3, 20] and used to  
59 identify host factors needed for the development of Pf liver schizont such as SR-B1 [10, 21,  
60 22] and glutamine synthetase [23]. A well-known phenomenon of *in vitro* cultured PHHs,  
61 however, is the quick loss of hepatic features [24, 25], yet its impact has not been explored in  
62 Pf liver stages and may hinder the discovery of host factors that are important for full  
63 maturation of liver schizonts. Establishment of an *in vitro* hepatocyte model that preserve  
64 hepatocyte features to allow for late-stage Pf maturation is therefore a prerogative and the next  
65 logical frontier in research. The loss of functional hepatic features is controlled by specific host  
66 signalling pathways [24] of which, their potential impact on parasite development have not  
67 been previously examined.

68

69 Here, we set out to 1) identify the impact of loss of hepatic functions in *in vitro* hepatocytes  
70 and their permissiveness to Pf infection, 2) improve and stabilize hepatocyte culture conditions  
71 for Pf permissiveness, facilitating complete schizont development and 3) identify host  
72 pathways in hepatocytes that influence the developmental kinetics of Pf liver stages. Using  
73 RNAseq to compare the transcriptomics profile between the freshly isolated and cultured PHH,  
74 we identified upregulation of the Wnt (Wingless and Int 1), TGF- $\beta$  (Transforming Growth  
75 Factor Beta), Notch and Rho signalling pathways. Treatment with specific chemical  
76 antagonists of some pathways led to improvement in Pf schizont development for some  
77 pathways. Furthermore, the Wnt pathway was shown to be most influential in determining the  
78 size of the growing Pf schizont.

79

## 80 **Results:**

### 81 ***In vitro* cultured PHHs lose permissibility for Pf liver stage infection and development**

82 Traditionally fresh primary human hepatocytes (PHH) are cultured in standard medium  
83 containing human sera (WBH) [23, 26, 27] and infected with Pf at 48 hours after plating.  
84 However, cultured hepatocytes quickly lose their cellular identity, and this may impact on the  
85 host cells' permissibility to sustain Pf infection. To investigate the effect of longer culturing,  
86 we infected PHH at different time points post-plating (p.p) with different Pf strains with  
87 different developmental kinetics (PfNF54, PfNF175 and PfNF135 [23]); schizont numbers  
88 were evaluated at five days post-infection (p.i) (Figure 1A). We observed a sharp decrease in  
89 number of schizonts in relation to the p.p. period for all Pf strains tested with the most drastic  
90 decline occurring between days 2 and 5 p.p. This reduction in the number of infected cells  
91 could not be explained by a decrease in the number of viable hepatocytes, which became  
92 prominent only after day 9 p.p (Figure 1C).

93

94 A previous study has shown that medium containing human sera drastically affects function of  
95 hepatocytes [21]. Therefore, we examined the impact of sera on hepatocyte permissiveness for  
96 parasite development via the removal of sera (WB versus WBH) (Figure S1). Only mild  
97 improvements in schizont numbers were observed in sera negative medium (WB) as well as  
98 presence of the maturation marker PfMSP1. We hence concluded that a novel hepatic culture  
99 medium is needed to return schizont numbers to those of day 2 p.p. PHH. A serum replacement  
100 supplement (B27) on a William's E Glutamax base was tested given its beneficial effect for

101 hepatic differentiation of stem cells [28] and hepatic organoids [29, 30] as well as other hepatic  
102 culture systems [24]. Addition of B27 to into the basal medium William's E Glutamax  
103 substantially delayed the loss of hepatocyte permissiveness by at least 7 days (Figure 1D).  
104 However, this was not due to changes in hepatocyte numbers which remained comparable to  
105 the WBH medium thus reflecting a change in the phenotype of the PHHs (Figure 1E).

106

107 Irrespective of these positive effects on Pf infections, uninfected PHHs cultured for 7 days  
108 displayed a transcriptional profile that was vastly different from freshly isolated PHH showing  
109 an upregulation of 2403 gene transcripts and a down regulation of 2732 genes (Figure 1G). The  
110 most significantly up-regulated genes were those involved in actin filament organization, cell-  
111 substrate adhesions, wound healing and extracellular matrix organization (Figure 1H). All these  
112 pathways are classically associated with epithelial to mesenchymal transition (EMT) [3]. As  
113 for down-regulated genes, we found a strong enrichment for those involved in metabolism i.e.  
114 small molecule catabolism, fatty acid metabolism, organic acid catabolism (Figure 1F).  
115 Together, while serum replacement (via B27) has a substantial positive effect on PHH  
116 permissiveness to Pf infection, it cannot fully prevent the loss of hepatic functions, which may  
117 be potentially relevant for the maturation of liver schizonts.

118

### 119 ***Specific host signal transduction pathways influence Pf liver stage development***

120 Testing the potential relevance of specific signalling pathways in culture-induced upregulation  
121 of genes (Figure 1F) showed a strong enrichment of genes associated with Wnt (Wingless and  
122 Int-1) signalling, Ras protein signalling, transforming growth factor beta (TGF- $\beta$ ), intrinsic  
123 apoptotic signalling pathway and Notch signalling pathways (Figure 2A). Compared to the  
124 fresh PHH, genes involved in the Wnt, TGF- $\beta$  and Notch pathways were strongly upregulated  
125 (Figure 2B-D), while BMP and Adenylyl-cyclase pathways mildly upregulated in B27 cultured  
126 PHH (Figure 2E). To examine the impact of these host pathway on Pf liver stage development,  
127 we treated PHH for 6-8 days p.p., with selective modulators of the individual pathways (IWP2,  
128 SB431542, DAPT, LDN193189 and Forskolin) (Figure 2F-J). Quantitative measurements  
129 assessed the replication (size, nuclear DNA content via DAPI; Figure 2F-G), health (human  
130 glutamine synthetase: hGS; Figure S2B-C) and maturation (PfMSP1; Figure 2I) status of the  
131 schizonts, respectively (Figure 2F-J, Figure S3). Modulation of both the BMP and the adenylyl-  
132 cyclase pathways through the usage of LDN193189 and Forskolin, respectively did not result  
133 in significant improvements in neither the number of schizonts (Figure 2F) nor phenotypic

134 parameters. DAPT-treated hepatocytes contained parasites displayed limited, but significant  
135 improvements in the number and the size of the schizonts. Improvements were found by  
136 SB431542 treatment for all five parameters most notably in number of schizonts and expression  
137 of maturation marker, PfMSP1. Similarly, in IWP2-treated hepatocytes schizonts showed  
138 improvements especially in size, DNA content and expression of PfMSP1. Finally, we tested a  
139 previously published cocktail containing all five of these inhibitors (5C) [24] (Figure S3).  
140 Interestingly, hepatocyte monolayers cultured in the presence of 5C showed poor support of  
141 PfNF175 schizont size and numbers (Figure S4D-J). Together, these data demonstrated that  
142 inhibition of specific host pathways, and in particular Wnt, TGF- $\beta$ , are important for supporting  
143 Pf permissiveness and/or schizont development.

144

145 ***Inhibition of the Wnt preserves metabolic profile and epithelial nature of PHHs and***  
146 ***improves developmental kinetics of Pf***

147 To study the earliest impact of Wnt pathway on Pf liver stage development, PHHs were treated  
148 with either IWP2 (6 days) prior to and during Pf infection (Figure 3A-F). IWP2 treatment  
149 promoted parasite development (size, nuclear content and PfMSP1 expression) from day 3 p.i.  
150 onwards for all Pf strains. To explain the developmental kinetics elicited by inhibition of the  
151 Wnt pathway, RNA sequencing was performed on hepatocytes cultured in either B27 or B27  
152 supplemented with IWP2 at day 5 p.i. Based on spatial proximity in the PCA space, B27  
153 cultured cells were very distinct from fresh hepatocytes (83% of variance, Figure 4A) as also  
154 evident from Figure 1F-H. This difference decreased upon addition of IWP2. Thus, treatments  
155 with IWP2 suppressed the transcriptional changes observed during the *in vitro* culture in B27  
156 medium (possibly associated with loss of native tissue context). Interestingly, 5C-treatment  
157 elicited additional transcriptional changes apparently not beneficial for Pf development (Figure  
158 3G). In IWP2-treated cells, 110 genes were upregulated and 312 genes downregulated relative  
159 to B27 cultured cells (mock, Figure 3I). Gene Ontology analysis of all the genes upregulated  
160 in IWP2 treated PHHs revealed enrichment of metabolism associated terms like fatty acid,  
161 alcohol and steroid metabolism (Figure 3J). Among the biological processes suppressed upon  
162 IWP2 treatment, we found enrichment of extra-cellular matrix organization, surface-adhesion,  
163 epithelium migration and Wnt-signalling (Figure 3H). We, hence, concluded that IWP2  
164 treatment improves the metabolism profile of cultured PHHs while simultaneously suppressing  
165 dedifferentiation processes like epithelium to mesenchymal transition, which associates with  
166 an improved developmental kinetics of liver schizonts.

167

168 ***Activation status of the Wnt pathway determines the size of Pf schizonts***

169 To further examine the impact of the Wnt pathway on Pf schizont size, we treated PHHs with  
170 the Wnt activator CHIR99021 prior and during PfNF135 and PfNF175 infection (Figure 4A-  
171 D). Compared to the B27 control, the number of schizonts were mildly increased for IWP2  
172 treated PHHs but not consistently changed for CHIR99021 (Figure S4A-B). As predicted,  
173 schizonts in CHIR99021-treated PHHs were slightly but significantly smaller than B27  
174 cultured schizonts on day 5 p.i. for both Pf strains. There was also a significant size decrease  
175 for PfNF135 but not for PfNF175 at day 7 which may be the result of arrested development of  
176 PfNF175 under B27 conditions (Figure S3). CHIR99021 treatment also resulted in a relative  
177 decrease in PfMSP1 expression significant for PfNF175. Thus, both inhibition and activation  
178 of the Wnt pathway in hepatocytes affects predominantly schizont size and maturation.  
179 Collectively, it demonstrates that the essential role played by the Wnt signalling pathway of  
180 host hepatocytes in determining schizont size and potentially developmental kinetics.

181

182 **Discussion**

183 In this study, we show that primary human hepatocytes in *in vitro* culture quickly lose their  
184 ability to sustain a Pf infection, irrespective of the parasite strain. This loss of permissibility  
185 coincides with up-regulation of specific signalling pathways in hepatocytes. Inhibition of  
186 individual up-regulated pathways (Wnt, TGF- $\beta$ , and Notch) results in the enhanced or  
187 maintained hepatocyte permissibility and/or improvement in schizont development. In  
188 addition, we identify the Wnt-pathway as an important host factor that determines the size and  
189 maturity of the developing schizonts.

190

191 Although combined blockage of all these up-regulated pathways greatly benefits hepatitis B  
192 virus infection as shown previously [19], it appears detrimental to hepatocytes permissiveness  
193 and development of Pf as shown in this study (Figure S4). This could be due to the differing  
194 intracellular host requirements by the two distinct pathogens: for example, the intrahepatic  
195 growth of HBV is 72 hours compared to the 7 days of Pf. Furthermore, 5C treatment appear to  
196 exert transcriptional and/or cellular changes beyond the prevention of EMT (Figure 3A). In  
197 case of Pf, we show here that specific individual host pathways rather than the combination of  
198 all pathways bring strong improvement on parasite development.

199

200 We find that the inhibition of the Wnt pathway in cultured hepatocytes have a marked effect on  
201 parasite size and maturation. This increase in parasites size is concordant with the upregulation  
202 of genes involved in lipid, alcohol and steroid metabolism (Figure 4). While general metabolic  
203 health of hepatocyte is conceivably beneficial for parasite growth, fatty acid synthesis in  
204 particular is relevant to parasite development and formation of hepatic merozoites [31].  
205 Furthermore, upon Wnt inhibition we find a downregulation of genes typical for EMT  
206 transition. In the context of *in vitro* cultures EMT is mainly due to the loss of tissue  
207 environment. EMT however can also occur *in vivo* during liver fibrosis [32] and might  
208 influence liver stage infection.

209

210 While our study highlights the relevance of the inhibition of the Wnt signaling pathway in *in*  
211 *vitro* cultures, this observation might also relevant during *in vivo* zonal differentiation of  
212 hepatocytes. It is well established that within the liver lobule hepatocytes display marked  
213 difference in gene expression and metabolism along the portal central axis (also refer to as  
214 zonation, [33]) and components of Wnt pathway are predominantly present in zone 3  
215 hepatocytes and heavily involved in maintaining hepatic zonation [34]. We have previously  
216 shown that Pf parasites strongly prefer zone 3 (pericentral) hepatocytes resulting in better  
217 parasite development [23], as similarly shown for *P. berghei* [35]. While zone 3 hepatocytes  
218 possess all components of the Wnt pathway i.e. the surface receptor and intracellular signalling  
219 components, the actual external Wnt ligand/signalling proteins may be possibly secreted by  
220 hepatocytes from neighbouring zones or other non-hepatocyte cells present in the liver [36]  
221 and may therefore also play a role in determining schizont size.

222

223 The slight increase in schizont size observed with the other pathway inhibitors may possibly  
224 also relate to the Wnt status. Schizonts grown in PHHs treated with forskolin (adenylate cyclase  
225 activator) or LDN193189 (inhibitor of Bone Morphogenic Protein pathway) are the relatively  
226 smaller with lower PfMSP1 expression. In forskolin treated schizonts, activated adenylate  
227 cyclase leads to increased levels of cAMP which in turn can activate the Wnt pathway [37, 38].  
228 However, the relationship between the BMP pathway (LDN193189) and the Wnt pathway is  
229 less obvious as the former can either inhibit or activate the Wnt pathway depending on the  
230 presence of wildtype of p53 or the loss of SMAD4 respectively [39]. This may explain the large  
231 variation observed in schizonts grown with LDN193189. Inhibition of the Notch pathway (by  
232 DAPT) maintains PHHs in their hepatocyte lineage (as opposed to a more bile ductal  
233 phenotype) as well as indirect inhibition the Wnt pathway [40]. This could hence explain the

234 observation that, schizonts grown in DAPT-treated PHHs are larger compared to the control  
235 B27 medium. Finally, TGF- $\beta$  signalling leads to the activation of the Wnt pathway [41]  
236 therefore its inhibition results in relative better schizonts as for size, nuclear content, and  
237 maturation.

238

239 Despite their differences in infectivity and phenotype, schizonts of all tested Pf strains are  
240 significantly larger and more mature in IWP2-treated PHHs than their counterparts in B27-  
241 treated PHHs. This larger size becomes significant during the process of schizont growth i.e.  
242 after day 3 p.i. and becomes prominent at day 5 p.i.; blockage of Wnt communication between  
243 infected- and uninfected cell could allow for better expansion of the growing schizont with less  
244 of host restriction. It has been estimated that an infected hepatocyte can expand up to 200 times  
245 its original volume to accommodate the growing Pf schizont [42]. This could necessitate some  
246 communication between the infected and uninfected hepatocyte and the Wnt signalling  
247 pathway may serve here as communication platform [33,35-37]. IWP2 specifically inhibits the  
248 enzyme, porcupine (Porcn), which is involved in transport of the wnt ligands [43]. One could  
249 hypothesize that neighbouring hepatocytes keep their strict size and volume via the steady basal  
250 level of wnt signalling and thereby limiting the growth of Pf schizonts [44]. A possible  
251 mechanism of action is summarised in Figure 5.

252

253 In conclusion, we show that PHHs cultured in the standard medium (WBH) rapidly lose their  
254 permissiveness to Pf liver stage development. This loss, however, can be substantially delayed  
255 by the usage of a defined serum replacement (B27) on top of a William's E Glutamax base.  
256 Furthermore, we identify three specific host signalling pathways (Wnt, TGF- $\beta$  and Notch) to  
257 modulate Pf liver stage development. In particular, the Wnt signalling pathway is shown in a  
258 novel role to control the size of the developing Pf schizont and is therefore a key factor in  
259 determining the Pf developmental kinetics for multiple parasite strains. Transcriptome analysis  
260 of Wnt inhibitor treated hepatocytes indicates that improvement of hepatic metabolism,  
261 prevention of EMT and cell division may lead to the positive effects on parasite size and  
262 maturation. Together, these findings provide steps forward in understanding the intricate  
263 interaction between host and parasite within infected hepatocytes which may benefit rational  
264 approaches for future therapeutic interventions.

265

266 **Materials and Methods**

267 **Ethics**

268 Primary human liver cells were freshly isolated from remnants of surgical material. The  
269 samples were anonymised and general approval for their use was granted in accordance with  
270 the Dutch ethical legislation as described in the Medical Research (Human Subjects) Act. It  
271 was confirmed by the Committee on Research involving Human Subjects in the region of  
272 Arnhem-Nijmegen, the Netherlands. Approval for use of remnant, anonymized surgical  
273 material for transcriptome analysis was specifically confirmed by the Committee on Research  
274 involving Human Subjects, in the region of Arnhem-Nijmegen, the Netherlands (CMO-2019-  
275 5908).

276

277 **PHH isolation from liver segments**

278 Primary human hepatocytes were isolated from patients undergoing elective partial  
279 hepatectomy as previously described [23, 27]. Freshly isolated hepatocytes are suspended in  
280 complete William's B medium (WB): William's E with glutamax (ThermoFisher Scientific:  
281 32551087), 1x Insulin/transferrin/selenium (ThermoFisher Scientific: 41400045), 1mM  
282 sodium pyruvate (ThermoFisher Scientific: 11360070), 1x MEM Non-essential amino acid  
283 solution (ThermoFisher Scientific: 11140035), 100 units/ml Penicillin-Streptomycin  
284 (ThermoFisher Scientific: 15140122) and 1.6 $\mu$ M of dexamethasone (Sigma Aldrich: D4902).  
285 PHHs were plated at 62,500 cells per well in 96 well format and kept in a 37°C (5% CO<sub>2</sub>)  
286 incubator with daily medium changes 96-well plates (Falcon: 353219) precoated with Type 1  
287 collagen solution from rat tail (Sigma Aldrich: C3867).

288

289 **Generation of sporozoites for liver infection**

290 Pf asexual and sexual stages were cultured in a semi-automatic system as described [45-47].  
291 *Anopheles stephensi* mosquitoes were reared at the Radboud University Medical Center  
292 Insectary (Nijmegen, the Netherlands) in accordance with standard operating procedures.  
293 Salivary glands from infected mosquitoes were hand-dissected and collected in WB medium.  
294 Collected glands were homogenized using home-made glass grinders and sporozoites were  
295 counted in a Burker-Turk chamber using phase-contrast microscopes. Immediately prior to  
296 infection of human hepatocytes, the sporozoites were supplemented with heat-inactivated  
297 human sera (HIHS) at 10% of the total volume (i.e. WBH).

298

299 **Medium compositions and duration**

300 *Different plating time after isolation (Figure 1B, C):* Isolated PHH were plated in WB medium.  
301 The following day, it was changed to WBH: this medium was refreshed daily until the end of  
302 the experiment on day 26 post plating. In figure 1D and E, isolated PHH were again plated in  
303 WB medium. The following day, it was changed to William's E with glutamax (ThermoFisher  
304 Scientific: 32551087) supplemented with 1x B27<sup>TM</sup> Supplement (ThermoFisher Scientific:  
305 17504044) and 100 units/ml Penicillin-Streptomycin (ThermoFisher Scientific: 15140122)  
306 which was referred to as B27 medium or mock in the article. On the day of infection, B27  
307 medium was removed and replaced with sporozoites suspended in WBH for three hours. After  
308 the infection process has occurred (i.e. after three hours), the WBH (sporozoite) medium was  
309 replaced with B27 medium until the conclusion of the experiment.

310

311 *Different medium treatments:* Isolated PHH were plated in WB medium. The following day, it  
312 was changed to the following medium conditions: B27 or B27 supplemented with 20 $\mu$ M of  
313 Forskolin (Enzo Life Sciences: BML-CN100-0010), or 10 $\mu$ M of SB431542 (Tocris: 1614), or  
314 0.5 $\mu$ M of IWP2 (Tocris: 3533), or 5 $\mu$ M of DAPT (Tocris: 2634) or 0.1 $\mu$ M of LDN193189  
315 (Tocris: 6053) or the combination of all the compound inhibitors (i.e. 5C). The hepatocytes  
316 were kept on this treatment for another 6 days (i.e. 7 days post plating) and then infected with  
317 sporozoites where the medium composition changes to WBH for three hours. After three hours,  
318 the monolayers were returned to their respective treatments.

319

320 *Investigating the Wnt pathway:* Isolated PHH were plated in WB medium. The following day,  
321 it was changed to the following medium conditions: B27 or B27 supplemented with 0.5 $\mu$ M of  
322 IWP2 or 3 $\mu$ M CHIR-99021 (Sigma-Aldrich: SML1046). The hepatocytes were kept on this  
323 treatment for another 6 days (i.e. 7 days post plating) and then infected with sporozoites where  
324 the medium composition changes to WBH for three hours. After three hours, the monolayers  
325 were returned to their respective treatments.

326

### 327 **Immunofluorescence readout**

328 Monolayers were fixed with 4% paraformaldehyde (ThermoFisher Scientific: 28906) for 10  
329 minutes and permeabilised using 1% Triton for 5 minutes. The samples are stained with the  
330 various primary Pf or human antibodies: Rabbit PfHSP70 at 1:75 dilution (StressMarq  
331 Biosciences: SPC186), Mouse PfMSP1 at 1:100 dilution (Sanaria and NIH/NIAD: AD233),  
332 and mouse human glutamine synthethase at 1:100-250 dilution (Abcam: ab64613). Secondary

333 antibodies were used at these following dilutions: Goat anti-rabbit Alexa Fluor 594 at 1:200  
334 dilution (ThermoFisher Scientific: A11012) and goat anti-mouse Alexa Fluor 488 at 1:200  
335 dilution (ThermoFisher Scientific: A11029). DAPI was used at 300 nM to stain the nuclear  
336 material of the monolayer.

337

### 338 **Microscopy**

339 The Zeiss LSM880 with Airyscan at 63x objectives (oil) and 2x zoom were used for detailed  
340 images. For high content images, the Zeiss Axio Observer Inverted Microscope Platform with  
341 AI assisted experimental startup was used. The images were acquired at 20x objectives with a  
342 numerical aperture of 0.8.

343

### 344 **Data analysis using FIJI**

345 *Infection rate:* For each well, 77 images were acquired in a tiled format. Approximately half  
346 (i.e. 39) images were counted on FIJI [48] for NF135 and NF175 infections. All the tiles were  
347 counted for NF54 due to the lower infection rate. The number of hepatic nuclei were counted  
348 for 1% of the total image (i.e. 7-10 images) and then extrapolated to get number of PHHs per  
349 well.

350

351 *Measurement of schizont size:* See Yang et al for further details [23]. Images obtained on the  
352 high content microscope were opened in FIJI. Random images were chosen until at least 100  
353 schizonts were measured (per well) unless the infection is with NF54 (at least 50 schizonts).  
354 Schizonts were selected using the region of interest (ROI) tool based on PfHSP70 positivity  
355 (red channel) and measured. This ROI mask is applied onto the other colour channels i.e. blue  
356 and green to obtain values of nuclear content (DAPI) and hGS or PfMSP1 signal. For hGS and  
357 PfMSP1, background non-specific staining was considered and subtracted from the final  
358 signal. Further details regarding the methods can be found in [21, 23].

359

### 360 **RNA Isolation and RNA sequencing library preparation**

361 Freshly isolated or in vitro cultured hepatocytes (mock or treatment) were homogenized in  
362 TRIzol solution and cryopreserved at -80°C. RNA was subsequently isolated using the Zymo  
363 research Direct zol RNA purification kit (Cat. No. #R2053). The isolated RNA was assessed  
364 for quality and quantified using Nanodrop and agarose gel electrophoresis. RNA sequencing  
365 libraries from isolated/purified RNA were prepared using the Kapa mRNA Hyperprep Kit (Cat.  
366 No. #KK8581) using slight modifications of the manufacturer's instructions for mRNA

367 enrichment method. The input total RNA for the various libraries was selected between 150ng,  
368 250ng or 500ng. The enriched mRNA was fragmented at 94°C for 6min and dA tailing  
369 performed at 55°C for 15min. In order to better capture the AT rich *Pf* transcriptome we  
370 modified the PCR protocol as follows: Initial denaturation at 98°C for 2min; Cycling  
371 denaturation at 98°C for 20sec, annealing + extension at 62°C for 2min; final extension at 62°C  
372 for 3min. We selected PCR cycles for library amplification (12, 11 and 10 respectively) based  
373 on starting input total RNA amount. The amplified libraries were quantified using Denovix  
374 dsDNA high sensitivity kit (Cat. No. #TN145)on a Qubit fluorometer. Further qualitative  
375 assessment of library size distribution was performed using the Agilent high sensitivity DNA  
376 kit (Cat. No. #5067-4626) on the Agilent 2100 bioanalyzer platform. Each library was  
377 sequenced in 42bp paired-end format for roughly 18 million reads on the Illumina Nextseq 500  
378 platform.

379

### 380 **RNA sequencing data analysis**

381 The sequencing endline fastq files were quality checked using FASTQC (ver. 0.11.9). The reads  
382 were subsequently trimmed for quality (-q 30) and adapter removal using the Trim\_Galore  
383 software (ver. 0.6.7). The trimmed reads were aligned onto the *Homo sapiens* ver. 38 genome  
384 using STAR aligner (ver. 2.7.10a). The reads mapped onto the respective genomes were  
385 counted using the –quantMode GeneCounts option in STAR. Reads mapping only to sense  
386 strand were corrected for batch effects stemming from different hepatocyte donors using the  
387 Combat-seq tool (sva package ver. 3.44.0). The batch corrected counts were used for  
388 subsequent differential expression analysis (for conditions/treatments) in DESeq2 package  
389 (ver. 1.36.0) in RStudio (ver. 4.2.2 “Innocent and Trusting”). PCA plot for the various  
390 sequenced libraries/samples was generated using plotPCA command. Volcano plots for  
391 differentially expressed genes and genes of interest were generated using custom scripts and  
392 ggplot2 (ver. 3.4.2) in R. Gene Ontology enrichment analysis was performed in using the  
393 clusterProfiler tool (ver. 4.4.4) with subsequent dot-plots generated using inbuilt functions in  
394 ggplot2. Heatmaps for differentially expressed genes were generated using the Morpheus  
395 online tool by Broad Institute.

396

### 397 **Statistical analysis**

398 For the majority of the experiments, at least three biological replicates were performed with  
399 two technical replicates. All statistical tests were performed using Prism 10. See figure  
400 legends for details regarding the statistical tests.

401

402 **Data availability**

403 The next-generation sequencing dataset associated with this study has been uploaded to Gene  
404 Expression Omnibus: GSE263643

405

406 The dataset comprises of:

407 The metadata sheet with information on experiments and samples

408 Raw data files: fastq files for RNA-sequencing

409 Processed data files: i) raw counts files generated from Combat-seq and ii) normalized count  
410 files generated from DESeq2

411

412 **Author contributions:**

413 AK, GJG, HW, AS, and ASPY performed the experiments. JHWdW coordinated the  
414 collection of the fresh human liver segments. ASPY and AK performed the analysis on the  
415 data. TB was involved in the writing and reading of the manuscript. AK, HW, RWS, RB and  
416 ASPY were involved in the conceptualization and writing of the manuscript.

417

418 **Acknowledgements:**

419 We are grateful for R. Stoter, W. Graumans, M. Vegte-Bolmer, A. Pouwelsen, L. Pelser-  
420 Posthumus and J. Kuhnen of the Malaria and Insectary Unit at the Radboud University  
421 Medical Center for parasite, mosquito and sporozoite production. We would like to thank the  
422 Microscopic Imaging Center (MIC) of the Radboud University for access to its facilities.  
423 A.S.P.Y was a recipient of the Veni grant from the Dutch Research Council (NWO) talent  
424 program (VI.Veni.192.171) and ZonMW Off-Road grant (04510012010050). A.K was  
425 supported by the Dutch Research Council (ZonMW-TOP-grant #91218010).

426 References:

- 427 1. WHO, W.H.O., *World Malaria Report 2022*. 2022.
- 428 2. Vaughan, A.M., et al., *Complete Plasmodium falciparum liver-stage development in*  
429 *liver-chimeric mice*. *J Clin Invest*, 2012. **122**(10): p. 3618-28.
- 430 3. Mo, A.X. and G. McGugan, *Understanding the Liver-Stage Biology of Malaria Parasites:*  
431 *Insights to Enable and Accelerate the Development of a Highly Efficacious Vaccine*. *Am*  
432 *J Trop Med Hyg*, 2018. **99**(4): p. 827-832.
- 433 4. Langlois, A.C., et al., *Plasmodium sporozoites can invade hepatocytic cells*  
434 *independently of the Ephrin receptor A2*. *PLoS One*, 2018. **13**(7): p. e0200032.
- 435 5. Silvie, O., et al., *Expression of human CD81 differently affects host cell susceptibility to*  
436 *malaria sporozoites depending on the Plasmodium species*. *Cell Microbiol*, 2006. **8**(7):  
437 p. 1134-46.
- 438 6. Silvie, O., et al., *Hepatocyte CD81 is required for Plasmodium falciparum and*  
439 *Plasmodium yoelii sporozoite infectivity*. *Nat Med*, 2003. **9**(1): p. 93-6.
- 440 7. Mancio-Silva, L., et al., *Nutrient sensing modulates malaria parasite virulence*. *Nature*,  
441 2017. **547**(7662): p. 213-216.
- 442 8. Lahree, A., J. Mello-Vieira, and M.M. Mota, *The nutrient games - Plasmodium*  
443 *metabolism during hepatic development*. *Trends Parasitol*, 2023. **39**(6): p. 445-460.
- 444 9. Postfai, D., et al., *Plasmodium parasite exploits host aquaporin-3 during liver stage*  
445 *malaria infection*. *PLoS Pathog*, 2018. **14**(5): p. e1007057.
- 446 10. Rodrigues, C.D., et al., *Host scavenger receptor SR-BI plays a dual role in the*  
447 *establishment of malaria parasite liver infection*. *Cell Host Microbe*, 2008. **4**(3): p. 271-  
448 82.
- 449 11. Real, E., et al., *Plasmodium UIS3 sequesters host LC3 to avoid elimination by autophagy*  
450 *in hepatocytes*. *Nat Microbiol*, 2018. **3**(1): p. 17-25.
- 451 12. Thieleke-Matos, C., et al., *Host cell autophagy contributes to Plasmodium liver*  
452 *development*. *Cell Microbiol*, 2016. **18**(3): p. 437-50.
- 453 13. van de Sand, C., et al., *The liver stage of Plasmodium berghei inhibits host cell*  
454 *apoptosis*. *Mol Microbiol*, 2005. **58**(3): p. 731-42.
- 455 14. Ebert, G., et al., *Targeting the Extrinsic Pathway of Hepatocyte Apoptosis Promotes*  
456 *Clearance of Plasmodium Liver Infection*. *Cell Rep*, 2020. **30**(13): p. 4343-4354 e4.
- 457 15. Soulard, V., et al., *Plasmodium falciparum full life cycle and Plasmodium ovale liver*  
458 *stages in humanized mice*. *Nat Commun*, 2015. **6**: p. 7690.
- 459 16. Sacci, J.B., Jr., et al., *Plasmodium falciparum infection and exoerythrocytic development*  
460 *in mice with chimeric human livers*. *Int J Parasitol*, 2006. **36**(3): p. 353-60.
- 461 17. Sattabongkot, J., et al., *Establishment of a human hepatocyte line that supports in vitro*  
462 *development of the exo-erythrocytic stages of the malaria parasites Plasmodium*  
463 *falciparum and P. vivax*. *Am J Trop Med Hyg*, 2006. **74**(5): p. 708-15.
- 464 18. Tweedell, R.E., et al., *The Selection of a Hepatocyte Cell Line Susceptible to Plasmodium*  
465 *falciparum Sporozoite Invasion That Is Associated With Expression of Glycan-3*. *Front*  
466 *Microbiol*, 2019. **10**: p. 127.
- 467 19. Kaushansky, A., et al., *Malaria parasites target the hepatocyte receptor EphA2 for*  
468 *successful host infection*. *Science*, 2015. **350**(6264): p. 1089-92.
- 469 20. Roth, A., et al., *A comprehensive model for assessment of liver stage therapies*  
470 *targeting Plasmodium vivax and Plasmodium falciparum*. *Nat Commun*, 2018. **9**(1): p.  
471 1837.

472 21. Yang, A.S.P., et al., *Development of Plasmodium falciparum liver-stages in hepatocytes*  
473 *derived from human fetal liver organoid cultures*. Nat Commun, 2023. **14**(1): p. 4631.

474 22. Yalaoui, S., et al., *Scavenger receptor BI boosts hepatocyte permissiveness to*  
475 *Plasmodium infection*. Cell Host Microbe, 2008. **4**(3): p. 283-92.

476 23. Yang, A.S.P., et al., *Zonal human hepatocytes are differentially permissive to*  
477 *Plasmodium falciparum malaria parasites*. EMBO J, 2021. **40**(6): p. e106583.

478 24. Xiang, C., et al., *Long-term functional maintenance of primary human hepatocytes in*  
479 *vitro*. Science, 2019. **364**(6438): p. 399-402.

480 25. Gomez-Lechon, M.J., et al., *Competency of different cell models to predict human*  
481 *hepatotoxic drugs*. Expert Opin Drug Metab Toxicol, 2014. **10**(11): p. 1553-68.

482 26. Mazier, D., et al., *Complete development of hepatic stages of Plasmodium falciparum*  
483 *in vitro*. Science, 1985. **227**(4685): p. 440-2.

484 27. Walk, J., et al., *Modest heterologous protection after Plasmodium falciparum*  
485 *sporozoite immunization: a double-blind randomized controlled clinical trial*. BMC  
486 Med, 2017. **15**(1): p. 168.

487 28. Mallanna, S.K. and S.A. Duncan, *Differentiation of hepatocytes from pluripotent stem*  
488 *cells*. Curr Protoc Stem Cell Biol, 2013. **26**: p. 1G 4 1-1G 4 13.

489 29. Huch, M., et al., *Long-term culture of genome-stable bipotent stem cells from adult*  
490 *human liver*. Cell, 2015. **160**(1-2): p. 299-312.

491 30. Hu, H., et al., *Long-Term Expansion of Functional Mouse and Human Hepatocytes as*  
492 *3D Organoids*. Cell, 2018. **175**(6): p. 1591-1606 e19.

493 31. van Schaijk, B.C., et al., *Type II fatty acid biosynthesis is essential for Plasmodium*  
494 *falciparum sporozoite development in the midgut of Anopheles mosquitoes*. Eukaryot  
495 Cell, 2014. **13**(5): p. 550-9.

496 32. Fabris, L., et al., *Revisiting Epithelial-to-Mesenchymal Transition in Liver Fibrosis: Clues*  
497 *for a Better Understanding of the "Reactive" Biliary Epithelial Phenotype*. Stem Cells  
498 Int, 2016. **2016**: p. 2953727.

499 33. Gebhardt, R., *Metabolic zonation of the liver: regulation and implications for liver*  
500 *function*. Pharmacol Ther, 1992. **53**(3): p. 275-354.

501 34. Russell, J.O. and S.P. Monga, *Wnt/beta-Catenin Signaling in Liver Development,*  
502 *Homeostasis, and Pathobiology*. Annu Rev Pathol, 2018. **13**: p. 351-378.

503 35. Afriat, A., et al., *A spatiotemporally resolved single-cell atlas of the Plasmodium liver*  
504 *stage*. Nature, 2022. **611**(7936): p. 563-569.

505 36. Zeng, G., et al., *Wnt'er in liver: Expression of Wnt and frizzled genes in mouse*.  
506 Hepatology, 2007. **45**(1): p. 195-204.

507 37. Suzuki, A., et al., *PTH/cAMP/PKA signaling facilitates canonical Wnt signaling via*  
508 *inactivation of glycogen synthase kinase-3beta in osteoblastic Saos-2 cells*. J Cell  
509 Biochem, 2008. **104**(1): p. 304-17.

510 38. Guo, R., et al., *Targeting Adenylate Cyclase Family: New Concept of Targeted Cancer*  
511 *Therapy*. Front Oncol, 2022. **12**: p. 829212.

512 39. Voorneveld, P.W., et al., *The BMP pathway either enhances or inhibits the Wnt pathway*  
513 *depending on the SMAD4 and p53 status in CRC*. Br J Cancer, 2015. **112**(1): p. 122-30.

514 40. Geisler, F. and M. Strazzabosco, *Emerging roles of Notch signaling in liver disease*.  
515 Hepatology, 2015. **61**(1): p. 382-92.

516 41. Bogaerts, E., et al., *The roles of transforming growth factor-beta, Wnt, Notch and*  
517 *hypoxia on liver progenitor cells in primary liver tumours (Review)*. Int J Oncol, 2014.  
518 **44**(4): p. 1015-22.

519 42. Vaughan, A.M. and S.H.I. Kappe, *Malaria Parasite Liver Infection and Exoerythrocytic*  
520 *Biology*. Cold Spring Harb Perspect Med, 2017. **7**(6).

521 43. Wang, X., et al., *The development of highly potent inhibitors for porcupine*. J Med  
522 Chem, 2013. **56**(6): p. 2700-4.

523 44. Acebron, S.P., et al., *Mitotic wnt signaling promotes protein stabilization and regulates*  
524 *cell size*. Mol Cell, 2014. **54**(4): p. 663-74.


525 45. Ifediba, T. and J.P. Vanderberg, *Complete in vitro maturation of Plasmodium falciparum*  
526 *gametocytes*. Nature, 1981. **294**(5839): p. 364-6.

527 46. Ponnudurai, T., et al., *Cultivation of fertile Plasmodium falciparum gametocytes in*  
528 *semi-automated systems. 1. Static cultures*. Trans R Soc Trop Med Hyg, 1982. **76**(6): p.  
529 812-8.


530 47. Ponnudurai, T., et al., *Infectivity of cultured Plasmodium falciparum gametocytes to*  
531 *mosquitoes*. Parasitology, 1989. **98 Pt 2**: p. 165-73.

532 48. Schindelin, J., et al., *Fiji: an open-source platform for biological-image analysis*. Nat  
533 Methods, 2012. **9**(7): p. 676-82.

534




**Figure 1: *Pf*-schizont development post-hepatocyte plating and transcriptomic profiles of primary human hepatocytes (PHH).** A) The solid arrows show the number of days after liver isolation (post-plating) and the lines with the clear triangles show the period of schizont development. B) The number of schizonts in PHH on day 5 post infection (p.i.) when infected on different days p.p. for parasite strains: NF175 (magenta;), NF135 (green; ) and NF54 (blue) in two independent experiments (except NF175). C) The number of PHHs present on day 5 p.i. on indicated days p.p for the specific parasite strains. For each independent experiment, the mean of three replicates is shown along with the standard deviation. The number of schizonts (D) and hepatocytes (E) on day 5 post invasion (p.i.) for NF135 and NF54 (n=1) for different infection times post plating (p.p.) cultured in B27 medium (grey). Dot-plots representing GO terms for biological processes of (F) downregulated and (H) upregulated in cultured hepatocytes. (G) Volcano plot representing the differential gene expression in cultured hepatocytes.




**Figure 2: Effect of signalling pathways on Pf schizont development.** A) Dot plots representing pathways that are upregulated in hepatocytes cultured in B27 for 7 days post plating. Heatmaps representing normalized expression of genes from (B)Wnt, (C)TGF $\beta$ , (D)Notch, (E)BMP and Adenylate cyclase signalling pathways deregulated in cultured vs freshly isolated hepatocytes. The data is scaled and representative of 2 biological replicates of RNA sequencing. The effect of specific host pathway inhibitors (IWP2, SB431542, DAPT, LDN193189 and Forskolin) on respectively schizont numbers (F; each dot is the average count of two technical replicates), size of schizonts (G; each dot is the median of at least 100 schizonts), total DAPI per schizont (H; each dot is the median of at least 100 schizonts), and total PfMSP1 per schizont (I; each dot is the median of at least 100 schizonts) on day 5 p.i.. The grey dotted line (per graphs F-I) shows the median measurements of schizonts grown in B27 control (from four independent experiments). The p-values from a Dunnett's multiple

comparisons test are shown. J) Representative confocal images (from four independent experiments) showing schizonts grown in B27 alone and B27 supplemented with Forskolin, SB431542, IWP2, DAPT and LDN193189 on day 5 p.i. stained with PfMSP1, PfHSP70 and DAPI. Scale bar is 25 microns.




**Figure 3: Effect of IWP2 on developmental kinetics of NF175 (A-B), NF135 (C-D) and NF54 (E-F) schizonts.** For each Pf strain, the number schizonts, the size of schizonts, the total DAPI content and total PfMSP1 content are shown from left to right. The schizonts are either grown in hepatocytes cultured in either B27 (grey) or B27 supplemented with IWP2 (orange) for 6 days prior to infection and also during schizont development on days 3, 5 and 7 p.i.. Note briefly that day 3 schizonts of NF175 was not examined. For the number of schizonts, the mean of three independent experiments, each with 2-3 internal replicates is shown. For the schizont size and the total DAPI per schizont, at least 100 schizonts per each of three independent experiments (with two replicates per experiment) were measured. The mean of the median from each experiment is plotted and the graph shows the mean with standard deviation. For the total MSP1 content, at least 100 schizonts per each of three independent experiments were measured. The median is plotted and the graph shows the mean with standard deviation. A Dunnett's multiple comparisons test is performed, and the p-values are displayed. B, D, F) Representative confocal images (from three independent experiments) showing NF175, NF135 and NF54 schizonts grown in B27 alone and B27 supplemented with IWP2 on day 7 p.i. stained

with MSP1, HSP70 and DAPI respectively. Scale bar is 25 microns. (G) PCA plot representing distinct transcriptional states of freshly isolated and in vitro cultured hepatocytes under mock, IWP2 (and 5C) treatment. Dot-plots representing GO terms for biological processed (H) downregulated and (I) upregulated in IWP2 treated hepatocytes. (J) Volcano plot representing the differential gene expression in IWP2 treated hepatocytes (downregulated genes in blue and upregulated in red; fold-change ( $\log_2$ )  $>2$ -fold and adjusted p-value  $\leq 0.1$ ).



**Figure 4: The impact of the Wnt signalling pathway on schizont size.** Hepatocytes treated with B27 or B27 supplemented with IWP2/CHIR99021 and infected with either NF175 (A) or NF135 (B). Schizont size (left), and total DAPI (middle) content are measured on days 5 and 7 post infection. The total amount of PfMSP1 per schizont was measured on day 7 p.i. (right). Each dot represents a schizont with at least 100 schizonts measured for three independent experiments. The median is shown, and a Dunn's multiple comparisons test is performed with the p values displayed. Representative confocal images (from three independent experiments) showing NF175 (C) and NF135 (D) schizonts B27 or B27 supplemented with IWP2/CHIR99021 on day 7 p.i. stained with MSP1, HSP70 and DAPI. Scale bar is 25 microns.



**Figure 5: Schematic of a possible mechanism in which the Wnt pathway controls Pf schizont development.** A) Under untreated and uninfected condition, there is a steady level of beta-catenin ( $\beta$ -catenin). In addition to its role in gene transcription,  $\beta$ -catenin is the intracellular component that links the cadherin adhesion molecules to actin filaments and therefore controls the “rigidity” of the cells in relation to its neighbours. B) In an infected hepatocyte (after 3 days post infection), the growing Pf schizont takes up so much of the hepatocyte volume that the trafficking of the Wnt ligands to the surface is disrupted. Wnt receptor of the neighbouring uninfected cells are not activated, and  $\beta$ -catenin molecules are degraded due to the phosphorylation of the enzyme, glycogen synthase kinase 3 (GSK3): this allows some flexibility in the uninfected neighbouring cells to accommodate the growth of the infected cell. However in these (uninfected cells), Wnt ligands are still present and can interact with the existing Wnt receptors on the infected hepatocytes to maintain some  $\beta$ -catenin in the infected cell, thus limiting the growth/size of the schizont. C) Under IWP2 treatment, Wnt ligands are not trafficked to the surface of both uninfected and infected hepatocytes due to the inhibition of the enzyme porcupine (target of IWP2). Porcupine “labels” (via palmitoylation) Wnt ligands for correct trafficking to the plasma membrane. As a result, Wnt receptors on both uninfected and infected cells are not activated and existing  $\beta$ -catenin are degraded leading to reduced connection between cadherin and actin filaments (i.e. cell-cell contacts) and ultimately reducing rigidity. D) Under CHIR99021 (GSK3 inhibitor) treatment,  $\beta$ -catenin in both uninfected and infected cells cannot be phosphorylated nor degraded. Both cell types are more rigid due to the improve connection between actin filaments and cadherin which severly limits the size of the Pf schizont.